⌕
Vera Therapeutics · VERA · Nasdaq
Tenet 41 · Weak
Compare
$26.20−2.85%At closeTenet 41 · Weak
$26.20−0.77 (−2.85%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Vera Therapeutics (VERA) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Defense WorldNov 10, 2026 · 04:18 ET
Vera Therapeutics, Inc. $VERA Shares Sold by CenterBook Partners LP

CenterBook Partners LP cut its stake in Vera Therapeutics, Inc. (NASDAQ: VERA) by 70.9% in a recent quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 52,308 sh…

● GlobeNewsWireNov 6, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera …

● MarketBeatNov 6, 2026 · 15:14 ET
Vera Therapeutics Q3 Earnings Call Highlights

Vera Therapeutics NASDAQ: VERA reported $10.3 million in third-quarter TRUTAKNA sales, its first partial quarter of commercial revenue, as the company pursues full U.S. approval for the kidney disease treatment.…

● Seeking AlphaNov 5, 2026 · 20:44 ET
Vera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call Transcript

Vera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call Transcript…

● Zacks Investment ResearchNov 5, 2026 · 18:46 ET
Vera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue Estimates

Vera Therapeutics, Inc. (VERA) came out with a quarterly loss of $1.3 per share versus the Zacks Consensus Estimate of a loss of $1.72. This compares to a loss of $1.26 per share a year ago.…

● GlobeNewsWireNov 5, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

TRUTAKNA® (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Patient Start Forms (PSFs) to date and $10.3 mill…

● GlobeNewsWireNov 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

BRISBANE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company's management team will participate in a fireside chat…

● MarketBeatOct 22, 2026 · 21:04 ET
Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results

Vera Therapeutics NASDAQ: VERA reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, marketed as TRUTAKNA, in adults with IgA nephropathy. The company presented the data at the American So…

● Seeking AlphaOct 22, 2026 · 19:17 ET
Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript

Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript…

● GlobeNewsWireOct 22, 2026 · 10:05 ETCOMPANY'S OWN WORDS
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in composi…

● GlobeNewsWireOct 20, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast

Investor webcast at 4:30 p.m. ET on October 22 to discuss ORIGIN 3 final efficacy results for TRUTAKNA ™ (atacicept-vymj) featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney Wee…

● GlobeNewsWireOct 2, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 29, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Ver…

● GlobeNewsWireOct 2, 2026 · 09:24 ETCOMPANY'S OWN WORDS
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgAN Will be A Featured Late-breaking Oral Presentation at Opening Plenary of ASN 2026…

● Seeking AlphaSep 15, 2026 · 20:01 ET
Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● BenzingaSep 15, 2026 · 12:28 ET
What's Going on With Vera Therapeutics Stock on Tuesday?

Vera Therapeutics Inc. (NASDAQ:VERA) shares are trading lower on Tuesday, after initially spiking higher, amid increased volatility after the company announced data from the ORIGIN 3 trial.…

● BarronsSep 15, 2026 · 12:03 ET
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results

Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.…

● InvezzSep 15, 2026 · 12:01 ET
Why is Vera Therapeutics stock reversing its premarket gains?

Vera Therapeutics (VERA) shares ripped higher in premarket trading on September 15 as investors reacted to landmark clinical data. The biopharmaceutical firm announced that its lead therapy TRUTAKNA (atacicept-vymj) met …

● Schaeffers ResearchSep 15, 2026 · 10:33 ET
Vera Stock Slides Despite Positive Phase 3 Results

Vera Therapeutics (NASDAQ:VERA) stock is down 2% to trade at $33.34, reversing earlier gains after disclosing positive late-stage ORIGIN 3 trial results for the company's TRUTAKNA drug.…

● GlobeNewsWireSep 15, 2026 · 06:30 ETCOMPANY'S OWN WORDS
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR, Prevented IgAN Disease Progression Through 2 Years in ORIGIN 3 Final Analysis…

● GlobeNewsWireSep 4, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Ver…

● GlobeNewsWireSep 1, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company's management team will present and participate in on…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just VERA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.